Sites Menu > APS - Seronegative APS - SNAPS

APS - Seronegative APS - SNAPS

Seronegative antiphospholipid syndrome associated with plasminogen activator inhibitor.

Lupus. 1994 Jun;3(3):201-3.

Further evidence of false negative screening for lupus anticoagulants

Thrombosis Research. Volume 121, Issue 4, 2008, Pages 477-484. Conclusions: LA activity can be demonstrated by assessment of screen and confirm data irrespective of screening test elevation above a reference range. Other workers have demonstrated this phenomenon in APTT using different study designs and it may be that standard interpretation criteria warrant re-assessment.

Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient 'seronegative' antiphospholipid syndrome?

Clin Exp Rheumatol. 1997 Sep-Oct;15(5):541-4. The antiphospholipid syndrome (APS) is characterized by the presence of venous and arterial thrombosis, recurrent fetal losses and thrombocytopenia, associated with the presence of antiphospholipid antibodies (aPL). This syndrome may be "primary" or may be associated with other diseases, mainly systemic lupus erythematosus (SLE). However, some patients present the clinical picture of this syndrome but without evidence of aPL in their serum. The term "seronegative" APS has been proposed to categorize these patients. Here with we present two patients with seronegativity for aPL at the time of a thrombotic event, but in whom these antibodies were detected 2 and 7 months later.

Seronegative antiphospholipid syndrome

Annals of the Rheumatic Diseases 2003;62:1127 © 2003 by BMJ Publishing Group Ltd & European League Against Rheumatism

Seronegative antiphospholipid syndrome

Annals of the Rheumatic Diseases 2004;63:608 © 2004 by BMJ Publishing Group Ltd & European League Against Rheumatism


By: Gale McCarty, MD, FACR, FACP "You don't have the syndrome because your tests are low level or negative" or "You have livedo, a heart valve problem, and thrombocytopenia, but these aren't listed as criteria for diagnosis" are comments made frequently by healthcare providers from many specialties to patients with clinical features suggesting the Antiphospholipid Antibody Syndrome (APS).

Pyoderma gangrenosum associated with the secondary antiphospholipid syndrome

Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called seronegative APS)

Ann Rheum Dis 2012;71:242-244 doi:10.1136/annrheumdis-2011-200614. Conclusions: Classic and SN-APS patients show similar clinical profiles. The results suggest that clinical management in patients with APS should not be based only on the presence of conventional aPL.

Search our Sites


AUTOMATE your Links Pages with!



The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2011 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295